Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Antibiotic Selection00:57

Antibiotic Selection

54.8K
Overview
54.8K
Pneumonia IV: Management01:28

Pneumonia IV: Management

360
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
360
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy01:16

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy

461
Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
461
Acute Pyelonephritis II: Diagnostic Studies and Management01:28

Acute Pyelonephritis II: Diagnostic Studies and Management

17
Introduction:For diagnosing acute pyelonephritis, a comprehensive patient history is collected to identify symptoms such as dysuria, frequent or urgent urination, flank pain, or costovertebral angle (CVA) tenderness that may suggest a kidney infection.Physical ExaminationDuring the physical examination, CVA tenderness is assessed. This involves gentle percussion over the costovertebral angle, where tenderness often indicates a kidney infection.Diagnostic TestsUrinalysis: Used to identify white...
17
Antimicrobial Effectiveness01:28

Antimicrobial Effectiveness

50
The effectiveness of antimicrobial agents depends on various factors influencing their ability to eliminate microbial populations. Larger microbial populations require more time for complete eradication, emphasizing the importance of population size analysis when evaluating antimicrobial efficacy.Microbial resistance to antimicrobial agents varies significantly. Highly resilient microorganisms include endospores, gram-negative bacteria, and non-enveloped viruses, while prions are exceptionally...
50
Biological Methods for Microbial Control01:28

Biological Methods for Microbial Control

64
Biological agents offer an effective means of controlling microbial growth by leveraging natural processes like predation, competition, and the secretion of antimicrobial substances.Predatory bacteria such as Bdellovibrio species target and kill pathogens like Salmonella and E. coli. They are widely used in poultry farms to control infections. Myxococcus species help combat plant-pathogenic fungi. These naturally occurring predators serve as eco-friendly alternatives to chemical pesticides and...
64

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Reimagining Bioequivalence for the Era of Complex Drug Products: A Quantitative Framework for Generic Drug Development.

Clinical and translational science·2026
Same author

From Precision to Personalized: Catalyzing AI-Enabled Innovation in Drug Development.

Clinical and translational science·2026
Same author

A Large Cohort Study to Identify Risk Factors of Acute Kidney Injury in Pediatric Patients Undergoing Intravenous Vancomycin Therapy.

Pharmacotherapy·2025
Same author

Evaluating Tranexamic Acid Dosing Strategies for Postpartum Hemorrhage: A Population Pharmacokinetic Approach in Pregnant Individuals.

Journal of clinical pharmacology·2025
Same author

Exploration of the potential impact of batch-to-batch variability on the establishment of pharmacokinetic bioequivalence for inhalation powder drug products.

CPT: pharmacometrics & systems pharmacology·2024
Same author

In memory of Dr. Thomas M. Ludden: a pioneer in pharmacometrics, a mentor to many, and a legacy of compassionate science.

Journal of pharmacokinetics and pharmacodynamics·2024

相关实验视频

Updated: Jul 24, 2025

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii
09:17

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii

Published on: January 2, 2017

14.7K

贝叶斯模型指导的抗微生物治疗在儿科.

Haden T Bunn1, Jogarao V S Gobburu1,2, Lindsey M Floryance1

  • 1Pumas-AI, Inc., Centreville, VA, United States.

Frontiers in pharmacology
|July 10, 2023
PubMed
概括

在儿童中优化抗菌剂剂量是很困难的,因为数据有限. 贝叶斯模型基于精确剂量提供了一个解决方案,以改善患者护理和治疗结果.

科学领域:

  • 药理学 药理学是指药理学的学科.
  • 儿科医学 儿科医学
  • 临床决策支持 临床决策支持

背景情况:

  • 抗微生物药物对于治疗感染至关重要,但最佳剂量,特别是在儿科,是具有挑战性的.
  • 从历史上看,有限的儿科临床试验导致了广泛的非标签药物使用.
  • 像儿科研究平等法案这样的监管努力旨在改善儿科药物数据,但进展缓慢.

研究的目的:

  • 描述儿童抗微生物剂量优化的挑战.
  • 以贝叶斯模型为基础的精确剂量作为一个可行的解决方案.
  • 鼓励在临床环境中采用先进的药物治疗策略.

主要方法:

  • 审查设计和实施剂量优化策略的挑战.
  • 支持贝叶斯模型的证据综合信息精确剂量.
  • 讨论综合临床决策支持平台.

主要成果:

  • 确定了小儿抗菌剂剂量策略中的重大障碍.
  • 证明了贝叶斯模型准确剂量的潜力,以克服这些挑战.
  • 强调了基于模型的精确剂量工具的日益普及.

结论:

关键词:
抗微生物药物 抗微生物药物贝叶斯人 贝叶斯人 贝叶斯人儿科 儿科 儿科 儿科精确的剂量准确的剂量.治疗药物监测 治疗药物监测

更多相关视频

Author Spotlight: Characterizing Airway Environments to Advance Model Systems and Antimicrobial Discovery in Cystic Fibrosis and Chronic Respiratory Infections
06:19

Author Spotlight: Characterizing Airway Environments to Advance Model Systems and Antimicrobial Discovery in Cystic Fibrosis and Chronic Respiratory Infections

Published on: October 11, 2024

2.0K
Development of a Polymicrobial Colony Biofilm Model to Test Antimicrobials in Cystic Fibrosis
07:16

Development of a Polymicrobial Colony Biofilm Model to Test Antimicrobials in Cystic Fibrosis

Published on: September 20, 2024

1.1K

相关实验视频

Last Updated: Jul 24, 2025

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii
09:17

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii

Published on: January 2, 2017

14.7K
Author Spotlight: Characterizing Airway Environments to Advance Model Systems and Antimicrobial Discovery in Cystic Fibrosis and Chronic Respiratory Infections
06:19

Author Spotlight: Characterizing Airway Environments to Advance Model Systems and Antimicrobial Discovery in Cystic Fibrosis and Chronic Respiratory Infections

Published on: October 11, 2024

2.0K
Development of a Polymicrobial Colony Biofilm Model to Test Antimicrobials in Cystic Fibrosis
07:16

Development of a Polymicrobial Colony Biofilm Model to Test Antimicrobials in Cystic Fibrosis

Published on: September 20, 2024

1.1K
  • 贝叶斯模型的知情精确剂量解决了儿科抗菌药物治疗中的关键缺口.
  • 可访问的临床决策支持平台有助于实施精确剂量.
  • 鼓励临床医生支持这些先进的药物治疗技术,以改善患者的治疗结果.